How could Akeso's expansion of ivonescimab trials affect AstraZeneca?
Akeso's US trial expansion could challenge AstraZeneca's market position The expansion of Ivonescimab's clinical development into the United States through the Phase III EA2251 study increases the drug's global visibility and potential market impact. Ivonescimab, a PD-1/VEGF bispecific antibody, has already demonstrated positive results in head-to-head studies against competitors, including pembrolizumab. This new US trial, which evaluates Ivonescimab with chemotherapy against current immunotherapy-based standards of care, strengthens Akeso's confidence in achieving global success and reshaping standards of care in major cancers. Given that Akeso and AstraZeneca are already identified as direct competitors, this advancement puts increased competitive pressure on AstraZeneca's existing drug pipeline.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches AstraZeneca
-
Akeso and Icahn School of Medicine at Mount Sinai have partnered to expand clinical trials for ivonescimab into the United States, with site activations expected in Q4 2026. This collaboration marks the seventh international registrational Phase II/III clinical trial for ivonescimab. The new trial, EA2251, will evaluate ivonescimab with chemotherapy against current immunotherapy standards of care for biliary tract cancer.
The full event1independent outlet -
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody that has already demonstrated positive results in a Phase III head-to-head study against pembrolizumab. Akeso is using this drug as a cornerstone of its strategy to reshape standards of care in major cancers worldwide, directly competing with established therapies like those offered by AstraZeneca.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
British-Swedish pharmaceutical company
Everything about AstraZeneca
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The Phase III EA2251 study will explore Ivonescimab with chemotherapy against current immunotherapy-based standards of care in the US.manilatimes.net
- Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by Akeso.manilatimes.net
- Ivonescimab has demonstrated positive results in a Phase III head-to-head study against pembrolizumab.manilatimes.net
Why it matters
For AstraZeneca, the expansion of Ivonescimab into the US market represents a direct competitive threat to its existing oncology portfolio. Since Akeso and AstraZeneca are already known competitors, the successful validation of Ivonescimab in a major US trial could accelerate its adoption as a superior treatment option, potentially eroding AstraZeneca's market share and influencing the global standard of care in biliary tract cancer and other major tumor types.
This development is part of a broader trend in biopharma where innovative, multi-mechanism drugs are challenging established immunotherapy standards. Akeso is positioning Ivonescimab as a cornerstone of its IO2.0 + ADC2.0 strategy, aiming to become a global leader in biopharmaceuticals by offering first-in-class or best-in-class solutions.
What we don't know yet
- What specific outcomes will the Phase III EA2251 study yield regarding Ivonescimab's efficacy in the US?
- How quickly will the US regulatory process (FDA) move Ivonescimab toward market approval?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- manilatimes.netWednesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.